Want to see SLDB full AI Analyst Report?
Top Page
Solid Biosciences
(NASDAQ:SLDB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$10.00
▲(1.11% Upside)
Action:Reiterated
Date:08/07/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and substantial cash burn), which outweighs the balance-sheet benefit of low debt. Technicals are moderately supportive with the stock trading above major moving averages, but momentum indicators are not strongly bullish. Valuation is constrained by losses (negative P/E) and no dividend yield, while the key corporate event increases future financing flexibility but adds dilution risk.
Positive Factors
Low balance-sheet leverage
Modest leverage limits fixed financial obligations and provides greater flexibility to fund clinical programs. However, this strength is partly offset by ongoing losses and the possibility that future capital needs require equity issuance.
Negative Factors
No current commercial revenue
The absence of recurring product revenue leaves the company dependent on clinical success, partnerships or future approvals to establish a commercial funding base. Widening losses indicate that operating scale has not yet offset development costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low balance-sheet leverage
Modest leverage limits fixed financial obligations and provides greater flexibility to fund clinical programs. However, this strength is partly offset by ongoing losses and the possibility that future capital needs require equity issuance.
Read all positive factors
Solid Biosciences (SLDB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.06B
Dividend YieldN/A
Average Volume (3M)915.05K
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue GrowthN/A
EPS Growth31.81%
CountryUS
Employees121
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding107,225,235
10 Day Avg. Volume891,392
30 Day Avg. Volume915,055
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.17Price Target Upside93.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.76
Revenue Forecast (FY)N/A
Solid Biosciences Business Overview & Revenue Model
Company Description
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical...
How the Company Makes Money
Solid Biosciences is a clinical-stage biotechnology company; as such, it generally does not generate recurring revenue from marketed products unless it has an approved therapy (null for any marketed-product revenue specifics). Its revenue, when re...
Solid Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.09M | 13.62M |
| Gross Profit | -395.00K | -1.64M | -2.46M | -2.58M | 8.09M | 13.62M |
| EBITDA | -205.07M | -172.69M | -121.90M | -93.43M | -96.87M | -69.22M |
| Net Income | -207.10M | -174.32M | -124.70M | -96.02M | -85.98M | -72.19M |
Balance Sheet | ||||||
| Total Assets | 420.58M | 232.54M | 188.66M | 164.94M | 260.25M | 232.38M |
| Cash, Cash Equivalents and Short-Term Investments | 377.68M | 187.85M | 148.92M | 123.64M | 213.72M | 207.78M |
| Total Debt | 20.16M | 21.16M | 24.18M | 26.27M | 28.55M | 2.06M |
| Total Liabilities | 46.51M | 52.53M | 51.42M | 38.46M | 48.59M | 24.17M |
| Stockholders Equity | 374.07M | 180.01M | 137.25M | 126.48M | 211.67M | 208.21M |
Cash Flow | ||||||
| Free Cash Flow | -187.81M | -157.44M | -100.67M | -95.69M | -100.99M | -79.05M |
| Operating Cash Flow | -186.84M | -156.29M | -100.01M | -94.18M | -97.98M | -77.76M |
| Investing Cash Flow | -87.09M | -58.45M | -16.09M | 9.69M | 59.16M | -91.09M |
| Financing Cash Flow | 293.82M | 194.45M | 122.44M | 3.12M | 74.83M | 134.99M |
Solid Biosciences Risk Analysis
Solid Biosciences disclosed 90 risk factors in its most recent earnings report. Solid Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Solid Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $614.82M | -2.11 | -178.58% | ― | 287.93% | -21.91% | |
53 Neutral | $180.24M | -1.20 | -114.26% | ― | -62.08% | -2.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.06B | -5.38 | -72.28% | ― | ― | 31.81% | |
43 Neutral | $158.31M | -1.99 | 44.63% | ― | 3.03% | 57.71% | |
43 Neutral | $1.22B | -6.52 | -43.31% | ― | -83.86% | -646.52% |
* Healthcare Sector Average
SLDB
Solid Biosciences
10.29
4.54
78.87%
AUTL
Autolus Therapeutics
2.24
0.80
55.56%
KRRO
Korro Bio
11.97
-14.07
-54.03%
ADCT
ADC Therapeutics
1.32
-1.97
-59.88%
GLUE
Monte Rosa Therapeutics
14.22
9.22
184.40%
Solid Biosciences Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Solid Biosciences Updates Shelf for $200 Million Offering
Neutral
Aug 6, 2026
Solid Biosciences Inc. on August 6, 2026 filed a new prospectus supplement under its effective universal shelf registration statement to register the offer and sale of up to $200 million of common stock through an amended and restated sales agreem...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Solid Biosciences Shareholders Approve Directors and Share Increase
Positive
Jun 10, 2026
At its June 10, 2026 annual meeting, Solid Biosciences stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 annual meeting, and ratified, on an advisory basis, the appointment of Ilan Ganot a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.